Jazz Pharmaceuticals plc·4

Mar 9, 5:21 PM ET

Iannone Robert 4

4 · Jazz Pharmaceuticals plc · Filed Mar 9, 2026

Research Summary

AI-generated summary of this filing

Updated

Jazz Pharmaceuticals EVP Robert Iannone Withholds 6,209 Shares for Taxes

What Happened

  • Robert Iannone, EVP, Global Head of R&D & Chief Medical Officer at Jazz Pharmaceuticals (JAZZ), had 6,209 shares withheld to satisfy tax obligations tied to the vesting of previously granted restricted stock units. The shares were valued at $188.69 each, totaling approximately $1,171,576. This disposition (code F) reflects tax withholding, not an open-market sale.

Key Details

  • Transaction date: 2026-03-05; Filing date: 2026-03-09.
  • Shares involved: 6,209 shares withheld at $188.69 per share; total value ≈ $1,171,576.
  • Transaction code: F — shares withheld to cover tax obligations from RSU vesting (footnote confirms withholding).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • No 10b5-1 plan or late-filing flag noted in the supplied information.

Context

  • Tax-withholding dispositions are routine administrative actions when restricted stock units vest; they are not equivalent to a deliberate open-market sale and generally shouldn’t be read as a directional insider trade signal.

Insider Transaction Report

Form 4
Period: 2026-03-05
Iannone Robert
EVP, Global Head of R&D & CMO
Transactions
  • Tax Payment

    Ordinary Shares

    [F1]
    2026-03-05$188.69/sh6,209$1,171,57688,871 total
Footnotes (1)
  • [F1]Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Signature
By: /s/Paz Dizon, as attorney in fact For: Robert Iannone|2026-03-09

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT